Vir Biotechnology, Inc. Contracts & Agreements
95 Contracts & Agreements
- Business Finance (14 contracts)
- Business Operations (21)
- Human Resources (21)
- Intellectual Property (14)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (22)
- Amendment No. 1 to the Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration... (Filed With SEC on November 3, 2023)
- Other Transaction for Advanced Research (OTAR) between the Company and the United States of America Department of Health and Human Services, Administration for Strategic... (Filed With SEC on November 3, 2023)
- Separation Agreement between Vir Biotechnology International GmbH and Johanna Friedl-Naderer, dated September 23, 2023 (Filed With SEC on November 3, 2023)
- Amendment No. 1 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited dated May 27, 2022 (Filed With SEC on August 9, 2022)
- Termination Agreement between the Company and WuXi Biologics (Hong Kong) Limited dated May 16, 2022 (Filed With SEC on August 9, 2022)
- Amendment No. 5 to Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2021 (Filed With SEC on February 28, 2022)
- Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated November 5, 2021 (Filed With SEC on February 28, 2022)
- Amended and Restated Letter Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022 (Filed With SEC on February 28, 2022)
- Stock Purchase Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022 (Filed With SEC on February 28, 2022)
- Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated January 12, 2022 (Filed With SEC on February 28, 2022)
- Amended and Restated Employment Letter Agreement between the Company and Ann M. Hanly, dated May 4, 2021 (Filed With SEC on May 6, 2021)
- Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021 (Filed With SEC on May 6, 2021)
- Amendment 1 to Patent License Agreement dated as of March 25, 2020, between the Company and Xencor, Inc., dated February 23, 2021 (Filed With SEC on May 6, 2021)
- Amendment 1 to Patent License Agreement dated as of August 15, 2019, between the Company and Xencor, Inc., dated February 23, 2021 (Filed With SEC on May 6, 2021)
- Stock Purchase Agreement between the Company and Glaxo Group Limited, dated February 14, 2021 (Filed With SEC on May 6, 2021)
- Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated February 14, 2021 (Filed With SEC on May 6, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)
- Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 23, 2020 (Filed With SEC on February 25, 2021)
- Amendment No. 1 to License Agreement between the Company and MedImmune, LLC, dated September 1, 2020 (Filed With SEC on February 25, 2021)
- Amendment No. 4 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated December 8, 2020 (Filed With SEC on February 25, 2021)
- Second Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated September 28, 2020 (Filed With SEC on February 25, 2021)
- Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 22, 2020 (Filed With SEC on February 25, 2021)
- Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020 (Filed With SEC on November 10, 2020)
- Employment Letter Agreement between the Company and Steven Rice, dated August 22, 2019 (Filed With SEC on November 10, 2020)
- Amendment No. 3 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated May 29, 2020 (Filed With SEC on August 11, 2020)
- Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited and Beecham S.A., dated June 9, 2020 (Filed With SEC on July 6, 2020)
- Form of Underwriting Agreement (Filed With SEC on July 6, 2020)
- Amendment No. 3 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated April 1, 2020 (Filed With SEC on July 6, 2020)
- Preliminary Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated April 5, 2020 (Filed With SEC on July 6, 2020)
- Stock Purchase Agreement between the Company and Glaxo Group Limited, dated April 5, 2020 (Filed With SEC on July 6, 2020)
- Clinical Development and Manufacturing Agreement between the Company and Biogen Inc., dated May 22, 2020 (Filed With SEC on July 6, 2020)
- Binding Letter Agreement between the Company and Samsung Biologics Co., Ltd., dated April 9, 2020 (Filed With SEC on July 6, 2020)
- Development and Manufacturing Collaboration Agreement between the Company and Wuxi Biologics (Hong Kong) Limited, dated February 25, 2020 (Filed With SEC on July 6, 2020)
- Letter of Intent between the Company and Wuxi Biologics (Hong Kong) Limited, dated June 15, 2020 (Filed With SEC on July 6, 2020)
- Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated October 28, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 22, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 2 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated February 24, 2020 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Grant Agreement between the Company and the Bill & Melinda Gates Foundation, dated April 18, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (Filed With SEC on March 26, 2020)
- Amendment No. 2 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated March 3, 2020 (Filed With SEC on March 26, 2020)
- Amendment No. 1 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (Filed With SEC on March 26, 2020)
- First Amendment to Amended and Restated Employment Letter Agreement between the Company and Michael Kamarck, dated March 13, 2020 (Filed With SEC on March 26, 2020)
- Description of Capital Stock (Filed With SEC on March 26, 2020)
- Form of Common Stock Certificate of the Registrant (Filed With SEC on September 30, 2019)
- Form of Underwriting Agreement (Filed With SEC on September 30, 2019)
- Vir Biotechnology, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 30, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on September 30, 2019)
- Non-Employee Director Compensation Policy (Filed With SEC on September 30, 2019)
- Letter Agreement between the Registrant and Alnylam Pharmaceuticals, Inc., dated November 13, 2018 (Filed With SEC on September 3, 2019)
- License Agreement between the Registrant and MedImmune, LLC, dated September 7, 2018 (Filed With SEC on September 3, 2019)
- Common Stock Issuance Agreement between the Registrant and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (Filed With SEC on September 3, 2019)
- Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (Filed With SEC on September 3, 2019)
- Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and Herbert Virgin, dated September 3, 2019 (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and Jay Parrish, dated August 27, 2019 (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and Phil Pang, dated August 27, 2019 (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and Michael Kamarck, dated August 28, 2019 (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and Howard Horn, dated August 27, 2019 (Filed With SEC on September 3, 2019)
- Amended and Restated Employment Letter Agreement between the Registrant and George Scangos, dated August 27, 2019 (Filed With SEC on September 3, 2019)
- Non-Employee Director Compensation Policy (Filed With SEC on September 3, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on September 3, 2019)
- Forms of Incentive Stock Option Notice and Agreement, Non-Qualified Stock Option Notice and Agreement, Restricted Stock Agreement and Restricted Stock Purchase Agreement under the... (Filed With SEC on September 3, 2019)
- Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended (Filed With SEC on September 3, 2019)
- Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 3, 2019)
- Forms of Option Grant Notice and Option Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 3, 2019)
- Vir Biotechnology, Inc. 2019 Equity Incentive Plan (Filed With SEC on September 3, 2019)
- Form of Indemnity Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on September 3, 2019)
- Amended and Restated Warrant, issued to Takeda Ventures, Inc (Filed With SEC on September 3, 2019)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated November 29, 2017 (Filed With SEC on September 3, 2019)
- Amendment to License Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated February 10, 2012 (Filed With SEC on September 3, 2019)
- Amendment 6 to Sub-License and Collaboration Agreement, dated September 7, 2018, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Lease Agreement between the Registrant and ARE-SAN FRANCISCO NO. 43, LLC, dated March 30, 2017 (Filed With SEC on September 3, 2019)
- First Amendment to Lease between the Registrant and ARE-SAN FRANCISCO NO. 43, LLC, dated April 10, 2019 (Filed With SEC on September 3, 2019)
- Patent License Agreement between the Registrant and Xencor, Inc., dated August 15, 2019 (Filed With SEC on September 3, 2019)
- Amendment 4 to Sub-License and Collaboration Agreement, dated August 29, 2016, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Amendment 3 to Sub-License and Collaboration Agreement, dated December 31, 2015, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated... (Filed With SEC on September 3, 2019)
- Amendment 2 to Sub-License and Collaboration Agreement, dated April 27, 2015, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Amendment 1 to Sub-License and Collaboration Agreement, dated April 19, 2013, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Sub-License and Collaboration Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March 20, 2012 (Filed With SEC on September 3, 2019)
- Amendment to Exclusive License Agreement between the Registrant and The Rockefeller University, dated May 17, 2019 (Filed With SEC on September 3, 2019)
- Exclusive License Agreement between the Registrant and The Rockefeller University, dated July 31, 2018 (Filed With SEC on September 3, 2019)
- Amendment Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated January 29, 2018 (Filed With SEC on September 3, 2019)
- Amendment 5 to Sub-License and Collaboration Agreement, dated July 15, 2017, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March... (Filed With SEC on September 3, 2019)
- Collaboration, Option, and License Agreement between the Registrant and Brii Biosciences Limited (previously named BiiG Therapeutics Limited), dated May 23, 2018 (Filed With SEC on September 3, 2019)
- Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated December 16, 2011 (Filed With SEC on September 3, 2019)
- Amendment to Amended and Restated Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute... (Filed With SEC on September 3, 2019)
- Amended and Restated Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research... (Filed With SEC on September 3, 2019)
- Grant Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated March 16, 2018 (Filed With SEC on September 3, 2019)
- Grant Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated January 26, 2018 (Filed With SEC on September 3, 2019)
- Letter Agreement between the Registrant and the Bill & Melinda Gates Foundation, dated December 23, 2016 (Filed With SEC on September 3, 2019)
- Securities Purchase Agreement between the Registrant, Humabs BioMed SA, the shareholders of Humabs set forth therein, the option-holders of Humabs set forth therein and Fortis... (Filed With SEC on September 3, 2019)
- Agreement and Plan of Merger between the Registrant, Vir Merger Sub, Inc., Agenovir Corporation, and Dr. Stephen R. Quake, dated January 2, 2018 (Filed With SEC on September 3, 2019)
- Letter Agreement between the Registrant and the stockholders of TomegaVax, Inc. set forth therein, dated September 12, 2016 (Filed With SEC on September 3, 2019)
- Second Revised and Restated Master License Agreement between the Registrant and Oregon Health & Science University, dated August 27, 2019 (Filed With SEC on September 3, 2019)